FACT: An open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer

Journal of Clinical Oncology

Volumn 30, Issue 16, 2012, Pages 1919-1925

  Bergh, Jonas ^a,b,i   Jönsson, Per Ebbe ^c   Lidbrink, Elisabet Kerstin ^b   Trudeau, Maureen ^f   Eiermann, Wolfgang ^g   Brattström, Daniel ^d   Lindemann, Justin P O ^h   Wiklund, Fredrik ^a   Henriksson, Roger ^a,b,e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^g Red Cross Clinic   (Germany)

^h ASTRAZENECA   (United Kingdom)

ⁱ UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; FULVESTRANT; GONADORELIN AGONIST;

ADULT; AGED; ARTHROPATHY; ARTICLE; CANCER RELAPSE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GASTROINTESTINAL DISEASE; HAZARD RATIO; HOT FLUSH; HUMAN; LIVER METASTASIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MORTALITY; OVERALL SURVIVAL; PARAMETERS; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOEMBOLISM; TIME TO PROGRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; RECEPTORS, ESTROGEN; RECURRENCE; TRIAZOLES;

EID: 84863892191     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.1095     Document Type: Article

References (23)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
2. Goldhirsch A, Woods WC, Coates AS, et al: Strategies for subtypes: Dealing with the diversity of breast cancer - Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736-1747, 2011
3. Drury S, Lambros M, Marchio C, et al: Gene copy number variability of oestrogen receptor-α in breast cancer. Breast Cancer Res Treat 106:S1, 2007 (suppl; abstr 404)
4. Dowsett M, Dunbier AK: Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 14:8019-8026, 2008
5. Gibson L: Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev (1):CD003370, 2007
6. Nabholtz JM, Buzdar A, Pollak M, et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial - Arimidex Study Group. J Clin Oncol 18:3758-3767, 2000
7. Mouridsen H, Gershanovich M, Sun Y, et al: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2101-2109, 2003 (Pubitemid 46606358)
8. Bonneterre J, Thurlimann B, Robertson JF, et al: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18:3748-3757, 2000
9. Wakeling AE: Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer 7:17-28, 2000
10. Beslija S, Bonneterre J, Burstein HJ, et al: Central European Cooperative Oncology Group (CECOG): Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 20:1771-1785, 2009
11. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al: Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 87:746-750, 1995
12. Robertson JF, Nicholson RI, Bundred NJ, et al: Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) -nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 61:6739-6746, 2001 (Pubitemid 32896496)
13. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
14. Jelovac D, Sabnis G, Long BJ, et al: Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res 65:5380-5389, 2005 (Pubitemid 40834290)
15. Macedo LF, Sabnis GJ, Goloubeva OG, et al: Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. Cancer Res 68:3516-3522, 2008
16. McCormack P, Sapunar F: Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer. Clin Breast Cancer 8:347-351, 2008
17. Robertson JFR, Erikstein B, Osborne CK, et al: Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer. Clin Pharmacokinet 43:529-538, 2004 (Pubitemid 38858305)
18. Mehta RS, Barlow WE, Albain KS, et al: A phase III randomized trial of anastrozole versus anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: SWOG S0226. San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-10, 2011 (abstr S1-1)
19. Di Leo A, Jerusalem G, Petruzelka L, et al: Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 28: 4594-4600, 2010
20. Robertson JFR, Lindemann JPO, Llombart-Cussac A, et al: A comparison of fulvestrant 500 mg with anastrozole as first-line treatment for advanced breast cancer: Follow-up analysis from the 'FIRST'Study. San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010 (abstr S1-3)
21. Robertson J, Dixon M, Sibbering M, et al: Tumor biomarker changes following pre-surgical treatment with 500 mg fulvestrant plus anastrozole versus 500 mg fulvestrant alone and 1 mg anastrozole alone. Cancer Res 69:S24, 2009 (suppl; abstr 24)
22. Lønning PE: Aromatase inhibitors in breast cancer. Endocr Relat Cancer 11:179-189, 2004
23. Lindström L, Howell S, Åström G, et al: Controversies in the management of metastatic breast cancer: Biologic evaluation of breast cancer - Should metastases be biopsied? Am Soc Clin Oncol Ed Book e7-e12, 2010